Testing Feasibility of Medication Adherence Problem Solving for Hypertension

Not Applicable

Completed

• Conditions: Hypertension; Adherence, Medication
• Interventions: Behavioral: Medication Adherence Problem Solving for Hypertension

• Registration Number: NCT05630521
• Lead Sponsor: Rush University Medical Center

Brief Summary

Adherence to medications for high blood pressure is key to improving blood pressure control and reducing the impact of cardiovascular disease. This project will test the feasibility of a tailored telehealth intervention to help patients improve adherence to blood pressure medication.

Detailed Description

Improving rates of blood pressure (BP) control among adults with hypertension is a key step in reducing rates of myocardial infarction, stroke, and heart failure, and lowering overall mortality from cardiovascular disease. Unfortunately, over half of patients prescribed medication for hypertension do not take their medication as prescribed, leading to a high percentage of patients (45%) who are unable to reach their target BP despite being treated with antihypertensive medication. Low medication adherence has been linked with higher rates of myocardial infarction, stroke, and angina, as well as reduced life expectancy. Previously tested interventions to improve adherence to antihypertensive regimens have had limited efficacy, largely due to an underlying assumption that a single, standardized intervention approach will address all patients' reasons for nonadherence. Tailoring adherence interventions using a Managed Problem Solving approach will permit addressing each patient's reasons for nonadherence. This project will test the feasibility of the Medication Adherence Problem Solving for Hypertension (MASH) telehealth intervention, tailored to each participant's reasons for low adherence to their antihypertensive medication. The intervention is designed to assess beliefs about hypertension, beliefs about medications, and barriers to effective medication-taking We will then deliver intervention strategies to address each patient's problematic beliefs and barriers, applying the 5 steps of Managed Problem Solving. The proposed project aims are to 1) Assess the feasibility of MASH to improve antihypertensive medication adherence among adults with hypertension (HTN) by tracking recruitment, participant engagement and satisfaction with the intervention, as well as retention in the study; 2) Obtain estimates of efficacy of MASH compared to usual care on improving antihypertensive adherence as measured by electronic monitoring caps (MEMS) and lowering BP among persons with elevated BP at baseline over 12 weeks to inform future power analyses for a full-scale trial; and 3) Obtain estimates of other model parameters necessary to inform future power analyses for a full-scale intervention trial, including (a) intervention effects on targeted reasons for nonadherence (beliefs, barriers, perceived side-effects) and their subsequent association with medication adherence; (b) strength of covariate effects (e.g. education, household size, employment); and (c) the within-participant correlation between assessments. If successful, this intervention can also serve as a model for improving medication adherence in other chronic conditions and improve health outcomes for the half of patients with chronic conditions who struggle to manage their medications.

Study Timeline

• Study First Submitted: 2022-11-04
• Study First Submitted QC: 2022-11-18
• Study First Posted: 2022-11-29
• Study Start: 2023-02-20
• Primary Completion: 2024-08-25
• Status Verified: 2024-09
• Study Completion: 2024-09-25
• Last Update Submitted: 2024-09-30
• Last Update Posted: 2024-10-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

1. Aged ≥ 18 years at time of study entry
2. Able to read, write, and converse in English
3. Have an active prescription for at least one HTN medication, reporting no antihypertensive prescription changes for 30 days prior to study entry
4. Have prescription drug coverage or participate in a prescription assistance program that covers medication costs.
5. Diagnosis of HTN, based on self-report or confirmed through medical records, where available. (Self-reported high BP has long been shown to be strongly correlated with presence of a HTN diagnosis.22-24 Self-report combined with presence of a prescribed HTN medication ensures that only participants with HTN will be included)
6. Must self-administer their own medications
7. Uncontrolled BP: systolic (SBP) ≥ 130 mmHg and/or diastolic (DBP) ≥ 80 mmHg at baseline
8. Nonadherent to HTN medication (Hill-Bone Medication Subscale score < 36) at screening

Exclusion Criteria

1. Acutely ill (e.g., symptoms of myocardial infarction, respiratory distress, stroke)
2. Patients who have end-stage renal disease (ESRD) and/or are on dialysis
3. In state of hypertensive crisis (SBP >180 and/or DBP > 120 mmHg) at the time of study screening. Any participant in hypertensive crisis will be referred to their health care provider immediately for further instruction and follow-up, per current guidelines2
4. BP measurement is contraindicated on both upper extremities
5. Terminal chronic illness with a life expectancy of 6 months or less

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Telehealth Intervention Group	Medication Adherence Problem Solving for Hypertension	The intervention components are: 1) educational modules and 2) bi-weekly telehealth visits for managed problem solving for 12 weeks. All intervention participants will be provided four educational modules, electronically and in print form. The modules are adapted from evidence-based materials developed by the American Heart Association, American College of Cardiology, and Centers for Disease Control and Prevention and cover (1) the causes of HTN, (2) how HTN raises risks for other chronic conditions, (3) medications for effectively managing high BP, and (4) how to manage barriers to medication adherence. Telehealth visits will supplement and reinforce the educational modules, addressing participants' specific knowledge needs and enhancing self-efficacy.

Primary Outcome Measures

Name	Time	Method
Recruitment rate	12 weeks	Number of patients enrolled in the study divided by number of patients invited to participate
Participant engagement	12 weeks	The number of intervention telehealth appointments kept divided by the number scheduled per-protocol
Patient satisfaction with intervention	12 weeks	Qualitative responses to questions about intervention delivery and content
Participant retention	12 weeks	% of randomized participants who complete the study

Secondary Outcome Measures

Name	Time	Method
Blood pressure	12 weeks	Resting blood pressure
Antihypertensive medication adherence	12 weeks	Adherence to antihypertensive medications as measured by electronic monitoring caps (MEMS)

Trial Locations

Locations (1)

Rush University Medical Center; 🇺🇸 Chicago, Illinois, United States